Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 2156001 approvals3 trials

SillaJen, Inc.

Official website

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

As of 2026-10-10, SillaJen, Inc. has 1 Korean MFDS drug approval, 23 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

SillaJen, Inc. was founded in March 2006 to develop anticancer drugs and listed on the KOSDAQ market in December 2016. The company is developing the oncolytic virus immunotherapy Pexa-Vec and mitotic checkpoint inhibitors targeting TTK and PLK1, while its pharmaceutical division has obtained approval for and markets five injectable prescription products. Pexa-Vec's Phase 3 hepatocellular carcinoma trial (PHOCUS) was terminated early on August 2, 2019, and SillaJen also operates an anticancer drug development and commerce business alongside its prescription drug R&D and sales division.

Products & technology

  • Pexa-VecOncolytic virus immunotherapy under development for multiple solid tumors
  • 프로파인퓨전주Injectable prescription drug
  • 뉴아미노펜프리믹스주Injectable prescription drug
  • 이브포프리믹스주Injectable prescription drug
  • 페라미비르주Injectable prescription drug
  • 펜타블루5주Injectable prescription drug

Regulatory approvals

data.go.kr

1 Korean MFDS drug approvals · 2021

  • MFDS drugNewpropa Injection2021-03-15
    Drug · Prescription · Approval202102323

Clinical trials

data.go.kr

3 MFDS clinical trial authorisations · 2015–2023 (Phase 1 2 · Phase 3 1)

  • Phase 1BAL08912023-04-12

    12 trial sites

  • Phase 3Pexa-Vec(Pexastimogene Devacirepvec)2016-04-29

    20 trial sites

  • Phase 1SJ-103β2015-09-11

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

펙사벡(Pexa-Vec) · 간암 등 고형암 · 임상 3상(PHOCUS, 간암, 조기종료) · The Phase 3 trial (PHOCUS) for hepatocellular carcinoma was terminated early on August 2, 2019.

유사분열 체크포인트 억제제(MCI) · 연구개발 진행중 · Under development to inhibit TTK and PLK1 kinases and disrupt the cancer cell cycle.

Key disclosures

KRX KIND via OpenDART
Show 11 more events

Publications

PubMed · affiliation-matched
Show 13 more publications

Patents

KIPRIS · applicant-matched
Show 81 more patents

AI reads

MAA server logs · IP-verified
236
Times AI engines pulled SillaJen, Inc.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

235
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

27
live 0
Last 7 days
175
live 0
Last 30 days
236
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot176
  • GoogleGoogleOther45
  • PerplexityPerplexityBot11
  • AnthropicClaudeBot2
  • MicrosoftBingbot1

Measured since Aug 27, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for SillaJen, Inc. and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

MEDIPOSTCO.,LTD.83

Medipost, founded in 2000 and KOSDAQ-listed in 2005, specializes in cord blood banking and stem cell therapeutics.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition